Toward an off-the-shelf vaccine for B-cell malignancies

Abstract

While idiotype vaccines have shown promise for B-cell malignancies, production is cumbersome; thus, targeting a common antigen on malignant B cells using an off-the-shelf approach would provide significant logistical advantages. (Figure Presented).